Phase I/Ii Study To Evaluate The Safety And Efficacy Of Tenalisib, A Novel Pi3k Delta/Gamma Dual Inhibitor In Combination With Pembrolizumab In Patients With Relapsed/Refractory Classical Hodgkin Lymphoma.
JOURNAL OF CLINICAL ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要